Learn More About the PROSERA Study
Now enrolling: The PROSERA phase 3 study of seralutinib in adults with pulmonary arterial hypertension.
Seralutinib Improves Pulmonary Arterial Blood Vessel Volume Distribution in Pulmonary Arterial Hypertension (PAH): Results of the TORREY Phase 2 Imaging Substudy